Can pharmacotherapy improve treatment outcomes in people with co-occurring major depressive and cocaine use disorders?

Angarita, Gustavo A.; Hadizadeh, Hasti; Cerdena, I. Laynez; Potenza, Marc N.

doi:10.1080/14656566.2021.1931684

Cited by 8 publications

(4 citation statements)

References 215 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings raise the intriguing and currently speculative notion that interventions promoting synaptic density (e.g., ketamine) may have potential treatment utility, and perhaps particularly in individuals with co-occurring depression (Angarita et al. 2021 ). Regarding subcortical regions such as the striatum, amygdala or hippocampus, there are insufficient studies to draw strong conclusions regarding treatment-GMV relationships, with some studies suggesting different directions of associations when linking GMVs to treatment outcomes (Moeller and Paulus 2018 ).…”

Section: Substance Use Disordersmentioning

confidence: 95%

See 1 more Smart Citation

Neural mechanisms linked to treatment outcomes and recovery in substance-related and addictive disorders

Mestre-Bach,

Potenza

2023

Dialogues in Clinical Neuroscience

Self Cite

View full text Add to dashboard Cite

The present review focuses on potential neural mechanisms underlying recovery from psychiatric conditions characterised by impaired impulse control, specifically substance use disorders, gambling disorder, and internet gaming disorder. Existing treatments (both pharmacological and psychological) for these addictions may impact brain processes, and these have been evaluated in neuroimaging studies. Medication challenge and short-term intervention administration will be considered with respect to treatment utility. Main models of addiction (e.g., dual process, reward deficiency syndrome) will be considered in the context of extant data. Additionally, advanced analytic approaches (e.g., machine-learning approaches) will be considered with respect to guiding treatment development efforts. Thus, this narrative review aims to provide directions for treatment development for addictive disorders.

show abstract

Section: Substance Use Disordersmentioning

confidence: 95%

“…Several recent articles have reviewed novel pharmacotherapies for cocaine use disorder (Angarita et al. 2021 ; Hadizadeh, Flores, Mayerson, et al. 2022 ; Hadizadeh, Flores, Nunes, et al.…”

Section: Substance Use Disordersmentioning

confidence: 99%

Neural mechanisms linked to treatment outcomes and recovery in substance-related and addictive disorders

Mestre-Bach,

Potenza

2023

Dialogues in Clinical Neuroscience

Self Cite

View full text Add to dashboard Cite

show abstract

“…To further complicate matters, substance use disorders (SUDs) frequently occur with affective disorders, including anxiety, major depressive disorder, and bipolar disorder. Such dual disorders have also increased during the COVID-19 pandemic − and are particularly difficult to treat when comorbid with psychostimulant use disorders (PSUD), , for which there is currently no FDA-approved pharmacotherapeutic.…”

Section: Introductionmentioning

confidence: 99%

Dopamine D₃/D₂ Receptor Ligands Based on Cariprazine for the Treatment of Psychostimulant Use Disorders That May Be Dual Diagnosed with Affective Disorders

et al. 2023

View full text Add to dashboard Cite

Highly selective dopamine D3 receptor (D3R) partial agonists/antagonists have been developed for the treatment of psychostimulant use disorders (PSUD). However, none have reached the clinic due to insufficient potency/efficacy or potential cardiotoxicity. Cariprazine, an FDA-approved drug for the treatment of schizophrenia and bipolar disorder, is a high-affinity D3R partial agonist (K i = 0.22 nM) with 3.6-fold selectivity over the homologous dopamine D2 receptor (D2R). We hypothesized that compounds that are moderately D3R/D2R-selective partial agonists/antagonists may be effective for the treatment of PSUD. By systematically modifying the parent molecule, we discovered partial agonists/antagonists, as measured in bioluminescence resonance energy transfer (BRET)-based assays, with high D3R affinities (K i = 0.14–50 nM) and moderate selectivity (<100-fold) over D2R. Cariprazine and two lead analogues, 13a and 13e, decreased cocaine self-administration (FR2; 1–10 mg/kg, i.p.) in rats, suggesting that partial agonists/antagonists with modest D3R/D2R selectivity may be effective in treating PSUD and potentially comorbidities with other affective disorders.

show abstract

“…Finally, microglial cell activation has been linked to depression, a common disorder co-morbid with SUDs [e.g., 25 - 27 ]. Indeed, alcohol, methamphetamine, depression and stress all enhance innate immune gene induction within microglia [ 14 ].…”

Section: Introductionmentioning

confidence: 99%

The incubation of cocaine craving is dissociated from changes in glial cell markers within prefrontal cortex and nucleus accumbens of rats

Webb

Sacramento

McCloskey

et al. 2022

Addiction Neuroscience

View full text Add to dashboard Cite

Can pharmacotherapy improve treatment outcomes in people with co-occurring major depressive and cocaine use disorders?

Cited by 8 publications

References 215 publications

Neural mechanisms linked to treatment outcomes and recovery in substance-related and addictive disorders

Neural mechanisms linked to treatment outcomes and recovery in substance-related and addictive disorders

Dopamine D₃/D₂ Receptor Ligands Based on Cariprazine for the Treatment of Psychostimulant Use Disorders That May Be Dual Diagnosed with Affective Disorders

The incubation of cocaine craving is dissociated from changes in glial cell markers within prefrontal cortex and nucleus accumbens of rats

Contact Info

Product

Resources

About

Can pharmacotherapy improve treatment outcomes in people with co-occurring major depressive and cocaine use disorders?

Cited by 8 publications

References 215 publications

Neural mechanisms linked to treatment outcomes and recovery in substance-related and addictive disorders

Neural mechanisms linked to treatment outcomes and recovery in substance-related and addictive disorders

Dopamine D3/D2 Receptor Ligands Based on Cariprazine for the Treatment of Psychostimulant Use Disorders That May Be Dual Diagnosed with Affective Disorders

The incubation of cocaine craving is dissociated from changes in glial cell markers within prefrontal cortex and nucleus accumbens of rats

Contact Info

Product

Resources

About

Dopamine D₃/D₂ Receptor Ligands Based on Cariprazine for the Treatment of Psychostimulant Use Disorders That May Be Dual Diagnosed with Affective Disorders